Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 µg intravitreal implant in people with diabetic macular edema

References

• Medicines and Healthcare Products Regulatory Agency. Public assessment report mutual recognition procedure ILUVIEN® 190 micrograms intravitreal implant in applicator (fluocinolone acetonide). 2015. Available at: http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con171936.pdf. [Last accessed December 6, 2016]
   Google Scholar
• Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012;119:2125-32
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Brown DM, Pearson A, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 2011;118:626-35
   PubMed Web of Science ®Google Scholar
• Early Treatment Diabetic Retinopathy Study research group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796-806
   Google Scholar
• Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. Two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology 2016;123:1351-9
   Google Scholar
• Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013;120:2013-22
   PubMed Web of Science ®Google Scholar
• Elman MJ, Ayala A, Bressler NM, et al. Intravitreal ranibizumab for diabetic macular edema with prompt vs. deferred laser treatment: 5-year randomized trial results. Ophthalmology 2015;122:375-81
   PubMed Web of Science ®Google Scholar
• The Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 2015;372:1193-203
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Questions and answers following the initial experience of the Adaptive Licensing Pilot project; 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2014/09/WC500172810.pdf. [Last accessed February 21, 2017]
   Google Scholar
• Rakic J-M, Leys A, Brié H, et al. Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study. Clin Ophthalmol 2013;7:1849-58
   PubMedGoogle Scholar
• Souied EH, Oubraham H, Mimoun G, et al. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice. Retina 2015;35:1743-9
   PubMed Web of Science ®Google Scholar
• Figueira J, Henriques J, Amaro M, et al. A nonrandomized, open-label, multicenter, phase 4 pilot study on the effect and safety of ILUVIEN® in chronic diabetic macular edema patients considered insufficiently responsive to available therapies (RESPOND). Ophthalmic Res 2017;57:166-72
   PubMed Web of Science ®Google Scholar
• Schmit-Eilenberger VK. A novel intravitreal fluocinolone acetonide implant (Iluvien(R)) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series. Clin Ophthalmol 2015;9:801-11
   PubMed Web of Science ®Google Scholar
• Elaraoud I, Andreatta W, Kidess A, et al. Use of flucinolone acetonide for patients with diabetic macular oedema: patient selection criteria and early outcomes in real world setting. BMC Ophthalmol 2016;16:3
   PubMed Web of Science ®Google Scholar
• Elaraoud I, Attawan A, Quhill F. Case series investigating the efficacy and safety of bilateral fluocinolone acetonide (ILUVIEN®) in patients with diabetic macular edema. Ophthalmol Ther 2016;5:95-104
   PubMed Web of Science ®Google Scholar
• Massin P, Erginay A, Dupas B, et al. Efficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study. Clin Ophthalmol 2016;10:1257-64
   PubMed Web of Science ®Google Scholar
• El-Ghrably I, Steel DHW, Habib M, et al. Diabetic macular edema outcomes in eyes treated with fluocinolone acetonide 0.2 µg/d intravitreal implant: real-world UK experience. Eur J Ophthalmol 2017;27:357-62
   PubMed Web of Science ®Google Scholar
• Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing snellen visual acuity measurements. Retina 2010;30:1046-50
   PubMed Web of Science ®Google Scholar
• Haukoos JS, Newgard CD. Advanced statistics: missing data in clinical research—part 1: an introduction and conceptual Framework. Acad Emerg Med 2007;14:662-8
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy; 2013. Available at: www.nice.org.uk/guidance/ta301. [Last accessed October 24, 2014]
   Google Scholar
• Cunha-Vaz J, Ashton P, Iezzi R, et al. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema. Ophthalmology 2014;121:1892-903
   PubMed Web of Science ®Google Scholar
• Bailey C, Chakravarthy U, Lotery A, et al. Real-world experience with 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom. Eye 2017 (epub ahead of print)
   PubMed Web of Science ®Google Scholar
• Parrish RK, Campochiaro PA, Pearson PA, et al. Characterization of intraocular pressure increases and management strategies following treatment with fluocinolone acetonide intravitreal implants in the fame trials. Ophthalmic Surg Lasers Imaging Retin 2016;47:426-35
   PubMed Web of Science ®Google Scholar
• Parrish RK, Traverso CE, Green K, et al. Quantitative assessment of optic nerve changes in patients with diabetic macular edema treated with fluocinolone acetonide vitreous implants. Ophthalmic Surg Lasers Imaging Retin 2016;47:418-25
   PubMed Web of Science ®Google Scholar